Orellanine specifically targets renal clear cell carcinoma

Area of Science:

• Nephrology
• Oncology
• Toxicology

Background:

• Renal cell carcinoma (RCC) is a major cause of cancer deaths, with clear cell RCC (ccRCC) being the most common subtype.
• Current metastatic RCC therapies improve survival but lack curative potential.
• Orellanine is a nephrotoxin known to selectively target proximal tubular epithelial cells.

Purpose of the Study:

• To investigate the hypothesis that orellanine's selective toxicity extends to ccRCC cells.
• To evaluate orellanine's efficacy against primary and metastatic ccRCC both in vitro and in vivo.

Main Methods:

• Dose-dependent cell death assays in proximal tubular cells and ccRCC cells (primary and cell lines).
• Analysis of orellanine's toxic mechanisms, including protein synthesis, cell metabolism, and apoptosis.
• In vivo studies using nude rats with human ccRCC xenografts to assess tumor reduction.

Main Results:

• Orellanine induced dose-dependent cell death in ccRCC cells and proximal tubular cells, with no observed toxicity in control cells.
• Orellanine's mechanism of action involves decreased protein synthesis, disrupted cell metabolism, and apoptosis induction.
• In vivo, orellanine treatment reduced viable tumor mass by over 90% in ccRCC xenografts.

Conclusions:

• Orellanine demonstrates selective toxicity towards ccRCC cells.
• Orellanine presents a potential novel therapeutic strategy for ccRCC, particularly for patients on dialysis.
• Further research into orellanine's application in ccRCC treatment is warranted.